×

BONE MARROW TRANSPL 2019 10.1038/s41409-019-0629-7
Benefits of additional cycles of bortezomib/thalidomide/dexamethasone (VTD) induction therapy compared to four cycles of VTD for newly diagnosed multiple myeloma
Lee1, YJ; Moon, JH; Sohn, SK; Kim, SJ; Jung, SH; Lee, JJ; Jo, JC; Shin, HJ; Lee, WS; Lee, JH; Bae, SH; Kim, MK; Lee, HS; Kim, K; Min, CK

ANN HEMATOL 2019 10.1007/s00277-019-03791-y
Multicenter retrospective analysis of the clinicopathologic features of monomorphic epitheliotropic intestinal T-cell lymphoma
Yi1, JH; Lee, GW; Do, YR; Jung, HR; Hong, JY; Yoon, DH; Suh, C; Choi, YS; Yi, SY; Sohn, BS; Kim, BS; Oh, SY; Park, J; Jo, JC; Lee, SS; Oh, YH; Kim, SJ; Kim, WS

MEDICINE 2019 10.1097/MD.0000000000017641
Changing trends in lymphoid neoplasm distribution in South Korea: analysis of 8615 cases from a single institute, 1997-2016 An observational study
Sim1, J; Takayama, T; Cho, J; Kim, SJ; Kim, WS; Ree, HJ; Ko, YH

BMC CANCER 2019 10.1186/s12885-019-6303-z
Ruxolitinib shows activity against Hodgkin lymphoma but not primary mediastinal large B-cell lymphoma
Kim1, SJ; Yoon, DH; Kang, HJ; Hong, JY; Lee, HS; Oh, SY; Shin, HJ; Kong, JH; Yi, JH; Sakamoto, K; Ko, YH; Huh, J; Lee, SS; Takeuchi, K; Shin, DY; Suh, C; Kim, WS

SCI REP-UK 2019 10.1038/s41598-019-51522-0
A clinicohaematological prognostic model for nasal-type natural killer/T-cell lymphoma: A multicenter study
Tan1, KM; Chia, B; Lim, JQ; Khoo, LP; Cheng, CL; Tan, L; Poon, E; Somasundaram, N; Farid, M; Tang, TPL; Tao, M; Cheah, DMZ; Laurensia, Y; Pang, JWL; Song, T; Tan, J; Huang, DC; Kim, SJ; Kim, WS; Ong, CK; Lim, ST; Chan, JY

J CLIN APHERESIS 2019 10.1002/jca.21734
Single-dose etoposide is an effective and safe protocol for stem cell mobilization in patients with multiple myeloma
Park1, Y; Kim, DS; Jeon, MJ; Lee, BH; Yu, ES; Kang, KW; Lee, SR; Sung, HJ; Nam, MH; Yoon, SY; Choi, CW; Kang, ES; Cho, D; Kim, K; Kim, BS; Kim, DW; Kim, SJ

INT J HEMATOL 2019 10.1007/s12185-019-02693-z
The Glasgow Prognostic Score is a significant predictor of peripheral T-cell lymphoma (PTCL) treated with CHOP-based chemotherapy and comparable with PTCL prognostic scores
Huh1, S; Oh, SY; Lee, S; Lee, JH; Kim, SH; Lee, GW; Kim, SJ; Kim, WS; Lee, HS; Jo, JC; Kim, MJ; Kwon, JH; Kim, HJ

CANCER RES TREAT 2019 10.4143/crt.2018.555
Body Cavity- Based Lymphoma in a Country with Low Human Immunodeficiency Virus Prevalence: A Series of 17 Cases from the Consortium for Improving Survival of Lymphoma
Shin1, J; Ko, YH; Oh, SY; Yoon, DH; Lee, JO; Kim, JS; Park, Y; Shin, HJ; Kim, SJ; Won, JH; Yoon, SS; Kim, WS; Koh, Y

ANN LAB MED 2019 10.3343/alm.2019.39.5.430
Flow Cytometric Analysis of T Cells in Hemophagocytic Lymphohistiocytosis
Park1, MS; Yoo, IY; Kim, HJ; Kim, SH; Kim, SJ; Cho, D

Cancer Med 2019 10.1002/cam4.2347
Real world experience of R-CHOP with or without consolidative radiotherapy vs DA-EPOCH-R in the first-line treatment of primary mediastinal B-cell lymphoma
Li Chan1, EH; Koh, LP; Lee, J; De Mel, S; Jeyasekharan, A; Liu, X; Tang, T; Lim, ST; Tao, M; Quek, R; Ras, MFB; Lee, YS; Diong, C; Tan, D; Kim, SJ; Chee, YL; Poon, LM

SCI REP-UK 2019 10.1038/s41598-019-48513-6
Prognostic values of novel biomarkers in patients with AL amyloidosis
Kim1, D; Lee, G; Choi, JO; Kim, K; Kim, S; Ju, ES; Jeon, ES

BIOL BLOOD MARROW TR 2019 10.1016/j.bbmt.2019.03.016
A Phase I/II Open-Label, Prospective, Multicenter Study to Evaluate the Efficacy and Safety of Lower Doses of Bortezomib Plus Busulfan and Melphalan as a Conditioning Regimen in Patients with Multiple Myeloma Undergoing Autologous Peripheral Blood Stem Cell Transplantation: The KMM103 Study
Park1, SS; Kim, K; Kim, SJ; Lee, JH; Yoon, SS; Mun, YC; Lee, JJ; Eom, HS; Kim, JS; Min, CK

LEUKEMIA LYMPHOMA 2019 10.1080/10428194.2019.1573998
Analysis of circulating tumor DNA by targeted ultra-deep sequencing across various non-Hodgkin lymphoma subtypes
Shin1, SH; Kim, YJ; Lee, D; Cho, D; Ko, YH; Cho, J; Park, WY; Park, D; Kim, SJ; Kim, WS

SCI REP-UK 2019 10.1038/s41598-019-44245-9
Associations of Electrocardiographic Parameters with Left Ventricular Longitudinal Strain and Prognosis in Cardiac Light Chain Amyloidosis
Kim1, D; Lee, GY; Choi, JO; Kim, K; Kim, SJ; Jeon, ES

CANCER RES TREAT 2019 10.4143/crt.2018.191
Comparison of Efficacy of Pembrolizumab between Epstein-Barr Virus-Positive and -Negative Relapsed or Refractory Non-Hodgkin Lymphomas
Kim1, SJ; Hyeon, J; Cho, I; Ko, YH; Kim, WS

CANCER RES TREAT 2019 10.4143/crt.2018.190
Radiation Therapy Outcome and Clinical Features of Duodenal-Type Follicular Lymphoma
Lee1, H; Oh, D; Yang, K; Ko, YH; Ahn, YC; Kim, WS; Kim, SJ

BONE MARROW TRANSPL 2019 10.1038/s41409-018-0253-y
A phase IV, randomized, multicenter, open-label trial comparing efficacy and systemic exposure for a standard weight-based dose versus a fixed dose of plerixafor in combination with G-CSF in patients with Non-Hodgkin's lymphoma weighing <= 70 kg
Kuruvilla1, J; Tzeng, CH; Cho, SG; Kim, SJ; Tang, JL; Su, YM; Wu, JY; Vargo, R; Cheverton, P

ANN HEMATOL 2019 10.1007/s00277-018-3516-1
Validation of the Marginal Zone Lymphoma International Prognostic Index
Hong1, J; Cho, J; Ko, YH; Kim, SJ; Kim, WS

CYTOKINE 2019 10.1016/j.cyto.2018.10.009
Profiles of serum cytokines and their clinical implications in patients with peripheral T-cell lymphoma
Yi1, JH; Ryu, KJ; Ko, YH; Kim, WS; Kim, SJ

LEUKEMIA LYMPHOMA 2019 10.1080/10428194.2018.1480772
Serum IL18 is associated with hemophagocytosis and poor survival in extranodal natural killer/T-cell lymphoma
Lim1, SW; Ryu, KJ; Lee, H; Ko, YH; Kim, WS; Kim, SJ